IgA Nephropathy in Elderly Patients

Ángel Sevillano(Universidad Complutense de Madrid), Monserrat Diaz(Puigvert Foundation), Fernando Caravaca‐Fontán(Universidad Complutense de Madrid), Clara Barrios(Hospital Del Mar), Carmen Bernis(Hospital Universitario de La Princesa), Jimena Cabrera(Hospital de Clínicas), Jesús Calviño(Hospital Universitario Lucus Augusti), L. Castillo(Hospital Universitari Joan XXIII de Tarragona), Carmen Cobelo(Hospital Universitario Lucus Augusti), Patricia Delgado-Mallén(Hospital Universitario de Canarias), Mario Espinosa(Hospital Universitario Reina Sofía), Gema Fernández‐Juárez(Hospital Universitario Fundación Alcorcón), María José Fernández‐Reyes(Hospital General De Segovia), Rosa García-Osuna(Hospital de Palamós), Patricia García(Hospital Clínico Universitario Virgen de la Victoria), Marián Goicoechea(Hospital General Universitario Gregorio Marañón), Fayna González-Cabrera(Hospital Universitario de Gran Canaria Doctor Negrín), Diomaris A. Guzmán(Hospital Regional Universitario de Málaga), Manuel Heras(Hospital General De Segovia), Guillermo Martín-Reyes(Hospital Regional Universitario de Málaga), Alberto Martínez(Hospital Universitari Joan XXIII de Tarragona), Teresa Olea(Hospital Universitario La Paz), Jessy Korina Peña(Hospital Universitario Príncipe de Asturias), Luís F. Quintana(Hospital Clínic de Barcelona), Cristina Rabasco(Hospital Universitario Reina Sofía), Katia López Revuelta(Hospital Universitario Fundación Alcorcón), Lida Rodas(Hospital Clínic de Barcelona), Nuria Rodríguez-Mendiola(Hospital Universitario Ramón y Cajal), Eva Rodríguez(Hospital Del Mar), Luz San Miguel(Puigvert Foundation), María Dolores Sánchez de la Nieta(Hospital General Universitario de Ciudad Real), Amir Shabaka(Hospital Clínico San Carlos), Milagros Sierra(Hospital San Pedro), A. Valera(Hospital Clínico Universitario Virgen de la Victoria), Mercedes Velo(Hospital Clínico San Carlos), Eduardo Verde(Hospital General Universitario Gregorio Marañón), José Ballarín(Puigvert Foundation), Óscar Noboa(Hospital de Clínicas), Juan Antonio Moreno(University of Córdoba), Eduardo Gutiérrez(Hospital Universitario 12 De Octubre), Manuel Praga(Universidad Complutense de Madrid), on behalf of the Spanish Group for the Study of Glomerular Diseases (GLOSEN)
Clinical Journal of the American Society of Nephrology
July 16, 2019
Cited by 43Open Access
Full Text

Abstract

BACKGROUND AND OBJECTIVES: Some studies suggest that the incidence of IgA nephropathy is increasing in older adults, but there is a lack of information about the epidemiology and behavior of the disease in that age group. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this retrospective multicentric study, we analyzed the incidence, forms of presentation, clinical and histologic characteristics, treatments received, and outcomes in a cohort of 151 patients ≥65 years old with biopsy-proven IgA nephropathy diagnosed between 1990 and 2015. The main outcome was a composite end point of kidney replacement therapy or death before kidney replacement therapy. RESULTS: value for trend =0.03). After asymptomatic urinary abnormalities (84 patients; 55%), AKI was the most common form of presentation (61 patients; 40%). Within the latter, 53 (86%) patients presented with hematuria-related AKI (gross hematuria and tubular necrosis associated with erythrocyte casts as the most important lesions in kidney biopsy), and eight patients presented with crescentic IgA nephropathy. Six (4%) patients presented with nephrotic syndrome. Among hematuria-related AKI, 18 (34%) patients were receiving oral anticoagulants, and this proportion rose to 42% among the 34 patients older than 72 years old who presented with hematuria-related AKI. For the whole cohort, survival rates without the composite end point were 74%, 48%, and 26% at 1, 2, and 5 years, respectively. Age, serum creatinine at presentation, and the degree of interstitial fibrosis in kidney biopsy were risk factors significantly associated with the outcome, whereas treatment with renin-angiotensin-aldosterone blockers was associated with a lower risk. Immunosuppressive treatments were not significantly associated with the outcome. CONCLUSIONS: The diagnosis of IgA nephropathy among older adults in Spain has progressively increased in recent years, and anticoagulant therapy may be partially responsible for this trend. Prognosis was poor. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2019_07_16_CJASNPodcast_19_08_.mp3.


Related Papers

No related papers found

Powered by citation graph analysis